MANNKIND CORP Convertible Notes Payable, Noncurrent
MANNKIND CORP (MNKD) had Convertible Notes Payable, Noncurrent of $36.05 million as of 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Notes and Loans, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2026-02-26
- 2024-12-31: Convertible Notes Payable, Noncurrent $36.05M.
- 2024-09-30: Convertible Notes Payable, Noncurrent $227.94M.
- 2024-06-30: Convertible Notes Payable, Noncurrent $227.58M.
- 2024-03-31: Convertible Notes Payable, Noncurrent $227.21M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2024-12-31 | $36.05M 10-K · filed 2026-02-26 |
| 2024-09-30 | $227.94M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $227.58M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $227.21M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $226.85M 10-K · filed 2025-02-26 |
| 2023-09-30 | $226.49M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $226.12M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $225.76M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $225.40M 10-K · filed 2024-02-27 |
| 2022-09-30 | $225.03M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $224.67M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $224.31M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $223.94M 10-K · filed 2023-02-23 |
| 2021-09-30 | $223.58M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $223.22M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $222.85M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $5.00M 10-K · filed 2021-02-25 |
| 2020-09-30 | $5.00M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.00M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $5.00M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $5.00M 10-K · filed 2021-02-25 |
| 2019-09-30 | $7.44M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $19.03M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $19.07M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $19.10M 10-K · filed 2020-02-25 |
| 2018-09-30 | $19.13M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $19.16M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $24.37M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $24.41M 10-K · filed 2019-02-26 |
| 2017-09-30 | $27.66M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $27.65M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $27.64M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $27.64M 10-K · filed 2018-02-27 |
| 2016-09-30 | $27.63M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $27.62M 10-Q/A · filed 2016-08-10 |
| 2016-03-31 | $27.62M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $27.61M 10-K · filed 2017-03-16 |
| 2015-09-30 | $27.61M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $35.71M 10-Q · filed 2015-08-10 |
| 2014-06-30 | $98.89M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $98.66M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $98.44M 10-K · filed 2015-03-02 |
| 2013-09-30 | $98.22M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $98.00M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $97.79M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $97.58M 10-K · filed 2014-03-03 |
| 2012-09-30 | $211.67M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $211.18M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $210.95M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $210.64M 10-K · filed 2013-03-18 |
| 2011-09-30 | $210.31M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $209.98M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $209.34M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |